共 50 条
- [41] A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy SubjectsCARDIOVASCULAR THERAPEUTICS, 2014, 32 (06) : 297 - 301Lunven, CatherinePaehler, TobiasPoitiers, FranckBrunet, AurelieRey, JacquesHanotin, CorinneSasiela, William J.
- [42] Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world studyNUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2022, 32 (03) : 684 - 691Iannuzzo, GabriellaBuonaiuto, AlessioCalcaterra, IleniaGentile, MarcoForte, FrancescoTripaldella, MariaDi Taranto, Maria D.Giacobbe, CarolaFortunato, GiulianaRubba, Paolo O.Di Minno, Matteo N. Dario
- [43] Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 studyEUROPEAN HEART JOURNAL, 2016, 37 (17) : 1360 - 1369Kastelein, John J. P.Nissen, Steven E.Rader, Daniel J.Hovingh, G. KeesWang, Ming-DauhShen, TongKrueger, Kathryn A.
- [44] Inhibition of PCSK9 Transcription by Berberine Involves Down-regulation of Hepatic HNF1 α Protein Expression through the Ubiquitin-Proteasome Degradation PathwayJOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (07) : 4047 - 4058Dong, BinLi, HaiSingh, Amar BahadurCao, AiqinLiu, Jingwen
- [45] Reduced VLDL clearance in Apoe-/-Npc1-/- mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levelsJOURNAL OF LIPID RESEARCH, 2010, 51 (09) : 2655 - 2663Ishibashi, MinakoMasson, DavidWesterterp, MaritWang, NanSayers, ScottLi, RongWelch, Carrie L.Tall, Alan R.
- [46] Interleukin-8 (IL-8) as a Potential Mediator of an Association between Trimethylamine N-Oxide (TMAO) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) among African Americans at Risk of Cardiovascular DiseaseMETABOLITES, 2022, 12 (12)Baginski, Alyssa M.Farmer, NicoleBaumer, YvonneWallen, Gwenyth R.Powell-Wiley, Tiffany M.
- [47] The Expression and Molecular Mechanisms of Matrix Metallo-proteinase-9 and Vascular Endothelial Growth Factor in Renal Interstitial Fibrosis in RatsCURRENT MOLECULAR MEDICINE, 2024, 24 (12) : 1540 - 1549Lin, ShujunLin, WenshanZhong, ZhiqingZhong, HongzhenZhou, TianbiaoWeng, Wenjuan
- [48] Screening of Salsola imbricata extract impacts against acrylamide induced hepatic toxicity in rats through the regulation of different global gene expressionTOXICOLOGY RESEARCH, 2025, 14 (02)El-Shehawi, Ahmed M.Sayed, SamyElseehy, Mona M.Alotaibi, SaqerAlharthi, Siraj B.Alsharif, GhadiSoliman, Mohamed
- [49] Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic studyBMJ OPEN, 2021, 11 (04):Cacciottolo, Paul J.Kostapanos, Michalis S.Sancho, Elena HernanPavey, HollyKaloyirou, FotiniVamvaka, EvangeliaHelmy, JoannaHubsch, AnnetteMcEniery, Carmel M.Wilkinson, Ian B.Cheriyan, Joseph
- [50] PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN studyAMERICAN HEART JOURNAL, 2024, 277 : 58 - 65Wu, Zhi-MingKan, JingYe, FeiYou, WeiWu, Xiang-QiTian, Nai-LiangLin, SongGe, ZhenLiu, Zhi-ZhongLi, Xiao-BoGao, Xiao-FeiChen, JingWang, YanWen, Shang-YuXie, PingCong, Hong-LiangLiu, Li-JunZeng, He-SongZhou, LeiLiu, FanZheng, Yong-HongLi, RuiJi, Hong-LeiZhou, Sheng-HuaZhao, Shou-MingQian, Xue-SongLuo, JunWang, XinZhang, Jun-JieChen, Shao-Liang